Advertisement
MIST vs RCUS
Which Stock Would AI Choose? Milestone Pharmaceuticals (MIST) vs. Arcus Biosciences (RCUS) Stock Comparison
Key Takeaways
- Milestone Pharmaceuticals (MIST) is now a commercial-stage cardiovascular biotech with an FDA-approved product launch underway, while Arcus Biosciences (RCUS) remains a clinical-stage oncology developer with no marketed drug.
- MIST is seeing accelerating prescription growth and expanding payer coverage for its CARDAMYST nasal spray, whereas RCUS recently completed a $250 million equity offering that diluted existing shareholders.
- Both companies are cash-intensive and loss-making, but their risk profiles differ sharply: commercial execution risk for MIST versus clinical and financing risk for RCUS.
- Tickeron AI Verdict: On observable trend consistency, near-term catalysts, and relative market positioning, Tickeron's AI currently favors MIST over RCUS.
- Explore deeper coverage on dedicated pages: MIST Major News, MIST Today's Price Move, RCUS Major News, and RCUS Today's Price Move.
- To see which strategies are generating the strongest signals right now, explore Trending AI Robots.
Introduction
This stock comparison examines two biopharmaceutical companies operating at very different stages of their lifecycles. MIST, Milestone Pharmaceuticals, has transitioned into a commercial-stage cardiovascular company, while RCUS, Arcus Biosciences, is a clinical-stage oncology developer advancing an investigational pipeline. For growth-oriented traders and healthcare-focused investors, the contrast is instructive: one company is working to convert early product traction into durable revenue, while the other is funding late-stage trials ahead of potential regulatory milestones. Comparing their relative performance, momentum, and market positioning helps clarify where observable fundamentals and sentiment currently diverge.
MIST Overview and Recent Performance
Milestone Pharmaceuticals is a biopharmaceutical company focused on innovative cardiovascular medicines. Its lead product, CARDAMYST (etripamil) nasal spray, is approved for treating paroxysmal supraventricular tachycardia (PSVT), a condition marked by sudden episodes of rapid heart rhythm. The company initiated its U.S. commercial launch in recent months and has reported steadily rising prescription volume, unique prescribers, and treated patients quarter over quarter. Management has cited expanding formulary coverage across major pharmacy benefit managers (PBMs, which administer prescription drug benefits for insurers and employers) as a key driver of access and future sales.
Beyond the launch, Milestone has broadened the etripamil program into atrial fibrillation with rapid ventricular rate (AFib-RVR), having initiated the Phase 3 ReVeRA-301 trial, and secured regulatory approval for etripamil in China. Recent weeks also brought new clinical data presentations at a major cardiology conference. Financial results remain early-stage, with modest product revenue and widening net losses, but the company ended recent quarters with a cash position it has said funds operations into the second half of 2027. Analysts covering the name have generally maintained positive ratings, reflecting confidence in the launch trajectory.
RCUS Overview and Recent Performance
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and immune diseases. Its most advanced asset is casdatifan, a HIF-2a inhibitor (a drug targeting a protein that promotes tumor growth) under study in clear cell renal cell carcinoma, a common form of kidney cancer. Recent ARC-20 data presentations highlighted encouraging response rates and progression-free survival across multiple lines of therapy, supporting an expanding registrational program, including the Phase 3 PEAK-1 study.
Financially, Arcus remains pre-revenue in the commercial sense, with collaboration revenue that has declined year over year and substantial net losses driven by research and development spending. In recent weeks the company raised capital through a public offering of common stock, generating net proceeds in the hundreds of millions of dollars to strengthen its balance sheet, while also introducing near-term share dilution. The company has indicated a cash runway extending into at least 2028. Sentiment reflects a balance between the promise of its casdatifan data and the costs and execution demands of advancing multiple late-stage trials.
Trending AI Robots
For traders who prefer a systematic approach to stock selection, Tickeron's Trending AI Robots page offers a curated view of its most relevant automated strategies. Tickeron maintains hundreds of AI trading bots that monitor thousands of tickers, but only the strategies best suited to current market conditions earn a place in the Trending section. These bots vary widely in trading style, timeframe, risk profile, statistical track record, and the set of tickers they trade, giving users a range of approaches rather than a single one-size-fits-all signal. Whether you are evaluating MIST, RCUS, or the broader market, exploring the Trending AI Robots can help you identify which automated strategies are generating the strongest current signals.
Head-to-Head Comparison
The two companies differ most fundamentally in their stage of development. MIST has an approved, launched product and is focused on commercial execution, reimbursement, and expanding its label into additional indications. Its growth story depends on converting early prescription momentum and payer coverage into accelerating revenue. RCUS, by contrast, has no marketed product; its value rests on clinical data and future regulatory outcomes, with revenue driven by collaborations rather than product sales.
Risk profiles also diverge. Milestone faces commercial ramp and reimbursement uncertainty, but its near-term catalysts are comparatively tangible: prescription trends, coverage decisions, and regulatory reviews. Arcus carries binary clinical-trial risk and has recently leaned on equity financing, creating dilution and downward pressure on relative performance. Sector exposure is another contrast, with MIST tied to cardiovascular medicine and RCUS to oncology and immunology. In terms of recent market sentiment, Milestone has benefited from a visible launch narrative and positive analyst coverage, while Arcus has contended with the dual signals of promising clinical data offset by financing-related pressure.
Tickeron AI Verdict
Weighing trend consistency, stability, and the proximity of observable catalysts, Tickeron's AI currently leans toward MIST in this comparison. Milestone's shift to a commercial-stage company introduces a measurable, recurring set of operating metrics, and its expanding payer coverage and label-expansion program offer multiple forward-looking catalysts. Arcus's casdatifan data are encouraging and its pipeline is substantial, but the stock's relative positioning has been complicated by a recent capital raise and declining collaboration revenue. Because this assessment is probabilistic rather than definitive, both tickers should be monitored as new data and financing developments reshape the picture.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIST is a Hold and RCUS is a Hold.
MIST in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 23, 2026
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MIST's RSI Indicator exited the oversold zone, 24 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 27, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 67 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RCUS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for RCUS moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 29 of the 34 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 62 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on RCUS as a result. In 75 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for RCUS just turned positive on November 04, 2026. Looking at past instances where RCUS's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
Following a +7.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 215 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for RCUS moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for RCUS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.016) is normal, around the industry mean (3.498). P/E Ratio (-4.640) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. RCUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MIST | RCUS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 85 | 78 | |
P/E GROWTH RATING 1..100 | 13 | 13 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RCUS's Valuation (60) in the Pharmaceuticals Major industry is in the same range as MIST (73). This means that RCUS’s stock grew similarly to MIST’s over the last 12 months.
RCUS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as MIST (100). This means that RCUS’s stock grew similarly to MIST’s over the last 12 months.
RCUS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as MIST (100). This means that RCUS’s stock grew similarly to MIST’s over the last 12 months.
RCUS's Price Growth Rating (78) in the Pharmaceuticals Major industry is in the same range as MIST (85). This means that RCUS’s stock grew similarly to MIST’s over the last 12 months.
RCUS's P/E Growth Rating (13) in the Pharmaceuticals Major industry is in the same range as MIST (13). This means that RCUS’s stock grew similarly to MIST’s over the last 12 months.
| MIST | RCUS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 81% |
| MACD ODDS (%) | 1 day ago 79% | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 78% |
| Advances ODDS (%) | 9 days ago 84% | 4 days ago 77% |
| Declines ODDS (%) | 3 days ago 85% | 11 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MIST’s FA Score shows that 1 FA rating(s) are green while RCUS’s FA Score has 1 green FA rating(s).
- MIST’s FA Score: 1 green, 4 red.
- RCUS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MIST’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 6 bullish TA indicator(s).
- MIST’s TA Score: 5 bullish, 3 bearish.
- RCUS’s TA Score: 6 bullish, 3 bearish.
Price Growth
MIST (@Biotechnology) experienced а -14.28% price change this week, while RCUS (@Biotechnology) price change was -2.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
MIST is expected to report earnings on Nov 13, 2026.
RCUS is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MIST and
Correlation & Price change
A.I.dvisor indicates that over the last year, MIST has been loosely correlated with RCUS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To MIST | 1D Price Change % | ||
|---|---|---|---|---|
| MIST | 100% | N/A | ||
| RCUS - MIST | 45% Loosely correlated | +0.70% | ||
| TSHA - MIST | 41% Loosely correlated | +0.12% | ||
| RCKT - MIST | 41% Loosely correlated | +1.22% | ||
| DYN - MIST | 40% Loosely correlated | +0.39% | ||
| NAMS - MIST | 40% Loosely correlated | +8.03% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QETH | 20.67 | 0.24 | +1.17% |
| Invesco Galaxy Ethereum ETF (QETH) | |||
| SUSL | 133.45 | 1.43 | +1.08% |
| iShares ESG MSCI USA Leaders ETF (SUSL) | |||
| FINT | 35.81 | 0.33 | +0.94% |
| Frontier Asset Total International Equity ETF | |||
| ACVU | 33.21 | 0.09 | +0.26% |
| Hartford Alpha Capture Value ETF (ACVU) | |||
| ABLS | 22.48 | -0.01 | -0.03% |
| Abacus FCF Small Cap Leaders ETF (ABLS) | |||